Our public private partnership aims to improve the lives of patients affected by the most common inflammatory skin diseases: atopic dermatitis and psoriasis
BIOMAP has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821511.